---
layout: post
title: New Drug Approvals 2014 - Pt. XI - Idelalisib (Zydelig™)
date: '2014-10-16T09:39:00.000+01:00'
author: Louisa
tags:
- Oral Drugs
- Small Molecule Drugs
- Enzyme drugs
- Black Box Warning Drugs
- 2014 New Drugs
- Combination Drugs
modified_time: '2014-10-16T09:39:23.036+01:00'
thumbnail: http://1.bp.blogspot.com/-mLqFLwVQQ0U/VD5OqrKvvqI/AAAAAAAAAMs/jcO1X6MPGC0/s72-c/Zydelig-logo.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-1336577963543743896
blogger_orig_url: http://chembl.blogspot.com/2014/10/new-drug-approvals-2014-pt-xi.html
---

<div class="separator" style="clear: both; text-align: center;">
<span style="font-family: Verdana, sans-serif; margin-left: 1em; margin-right: 1em;"><a href="http://1.bp.blogspot.com/-mLqFLwVQQ0U/VD5OqrKvvqI/AAAAAAAAAMs/jcO1X6MPGC0/s1600/Zydelig-logo.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://1.bp.blogspot.com/-mLqFLwVQQ0U/VD5OqrKvvqI/AAAAAAAAAMs/jcO1X6MPGC0/s1600/Zydelig-logo.png" /></a></span></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<span style="font-family: Verdana, sans-serif;"><br />
</span> <br />
<div class="separator" style="clear: both; text-align: center;">
<img alt="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,0,1,0,1,0,0,1,1" border="0" src="http://4.bp.blogspot.com/-cBrYZGMbDog/VD5V28rG-eI/AAAAAAAAANI/avj9iQFyTiU/s1600/warning.jpg" height="34" title="" width="320" /><span id="goog_707453262"></span><span id="goog_707453263"></span><a href="https://www.blogger.com/"></a></div>
<span style="font-family: Verdana, sans-serif;"><br />
</span> <br />
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>ATC Code: </b><a href="http://en.wikipedia.org/wiki/ATC_code_L01#L01X" target="_blank">L01XX47</a></span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>Wikipedia: </b><a href="http://en.wikipedia.org/wiki/Idelalisib" target="_blank">Idelalisib</a></span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>ChEMBL: </b><a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2216870" target="_blank">CHEMBL2216870</a></span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><br />
</span></div>
<span style="font-family: Verdana, sans-serif;">On July 23rd the <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm" target="_blank">FDA approved</a> Zydelig (<a href="http://en.wikipedia.org/wiki/Idelalisib" target="_blank">idelalisib</a>,&nbsp;GS-1101), as an orally-delivered drug to treat patients with three types of blood cancers.</span><br />
<span style="font-family: Verdana, sans-serif;">•<span class="Apple-tab-span" style="white-space: pre;"> </span>Relapsed chronic lymphocytic leukemia (CLL)</span><br />
<span style="font-family: Verdana, sans-serif;">•<span class="Apple-tab-span" style="white-space: pre;"> </span>Relapsed follicular B-cell, non-Hodgkin lymphoma &nbsp;(FL)</span><br />
<span style="font-family: Verdana, sans-serif;">•<span class="Apple-tab-span" style="white-space: pre;"> </span>Relapsed small lymphocytic lymphoma (SLL)</span><br />
<div>
<span style="font-family: Verdana, sans-serif;"><br />
</span></div>
<div>
<div>
<span style="font-family: Verdana, sans-serif;"><b>Blood cancer</b></span></div>
<div>
<span style="font-family: Verdana, sans-serif;">The three main categories of blood cancer are <a href="http://en.wikipedia.org/wiki/Leukemia" target="_blank">leukemia</a>, <a href="http://en.wikipedia.org/wiki/Lymphoma" target="_blank">lymphoma</a> and <a href="http://en.wikipedia.org/wiki/Multiple_myeloma" target="_blank">myeloma</a>. Lymphoma is also split into two types: <a href="http://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma" target="_blank">Hodgkin lymphoma</a> and <a href="http://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma" target="_blank">non-Hodgkin lymphoma</a>. Both leukemia and myeloma occur in the <a href="http://en.wikipedia.org/wiki/Bone_marrow" target="_blank">bone marrow</a>, whilst lymphoma is a cancer that is isolated to the lymphatic system. Acute leukemia is where there is an abundance of underdeveloped white blood cells that can’t function properly and chronic leukemia is where there are just far too many white blood cells, which is just as bad as having too few. Myeloma is where the plasma cells form tumours in the bone marrow.</span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><br />
</span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><br />
</span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><b>Idelalisib</b></span></div>
<div>
<span style="font-family: Verdana, sans-serif;">This drug is a <a href="http://en.wikipedia.org/wiki/Phosphoinositide_3-kinase_inhibitor" target="_blank">phosphoinositide 3-kinase inhibitor</a>, which works by blocking <a href="http://en.wikipedia.org/wiki/P110%CE%B4" target="_blank">P110σ</a>&nbsp;(<a href="https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL3130" target="_blank">CHEMBL3130</a>, <a href="http://www.uniprot.org/uniprot/O00329" target="_blank">Uniprot:O00329</a>), the delta isoform of the phosphoinositide 3-kinase enzyme, encoded in humans by the PIK3CD gene. This isoform plays a role in B-cell development, proliferation and function and is expressed predominantly in leukocytes.</span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><br />
</span></div>
</div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img border="0" src="http://2.bp.blogspot.com/-qVxX3bU0mrQ/VD5Q3Ty-uvI/AAAAAAAAAM4/G0N9cQxmiD0/s1600/drug.png" height="320" style="margin-left: auto; margin-right: auto;" width="284" /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: Verdana, sans-serif;"><b>Idelalisib</b></span></td></tr>
</tbody></table>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-qVxX3bU0mrQ/VD5Q3Ty-uvI/AAAAAAAAAM4/G0N9cQxmiD0/s1600/drug.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><span style="font-family: Verdana, sans-serif;"></span></a></div>
<div>
<div>
<span style="font-family: Verdana, sans-serif;"><b>Mode of action</b></span></div>
<div>
<span style="font-family: Verdana, sans-serif;">Idelalisib works on patients by inhibiting the <a href="http://en.wikipedia.org/wiki/Phosphoinositide_3-kinase" target="_blank">PI3 kinase</a> delta isoform (PI3Kδ), which plays an important role in malignant lymphocyte survival. It is the delta and gamma forms that are specific to the <a href="http://en.wikipedia.org/wiki/Haematopoiesis" target="_blank">hematopoietic</a> system. This treatment impairs the normal tracking of CLL lymph nodes. It can be used in conjunction with Rituxan (rituximab), an existing blood cancer treatment, for relapsed CLL and on its own for FL and SLL.</span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><br />
</span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><b>Clinical trials</b></span></div>
</div>
<div>
<span style="font-family: Verdana, sans-serif;">Clinical trials were carried out on 220 patients, with relapsed CLL, who were not healthy enough, due to co-existing medical conditions or damage from previous chemotherapy, to receive cytotoxic therapy. Patients were administered either idelalisib plus rituximab or a placebo and rituximab. Most of these patients were 65 years of age or older.</span></div>
<div>
<span style="font-family: Verdana, sans-serif;">After 24 weeks, 93% of the group who had taken the combination treatment were disease progression-free, compared to only 46% of the group who had received the placebo and rituximab combination.</span></div>
<div>
<span style="font-family: Verdana, sans-serif;">After 12 months, 90% of the dual drug combination group were alive, compared to 80% of the placebo-containing group. <a href="http://www.cancer.gov/clinicaltrials/results/summary/2014/idelalisib-CLL0314" target="_blank">[NCI]</a></span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><br />
</span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><b>Indication and Warnings</b></span></div>
<div>
<span style="font-family: Verdana, sans-serif;">This drug can be used in combination with rituximab or on its own, indicated for patients with relapsed conditions. There are several warnings for idelalisib, including hepatotoxicity, pneumonitis (fatal and serious), intestinal perforation and embyro-fetal toxicity. <a href="http://www.gilead.com/~/media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf" target="_blank">[FDA]</a></span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><br />
</span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><b>Trade Names</b></span></div>
<div>
<span style="font-family: Verdana, sans-serif;">Idelalisib was developed by Gildead Sciences and is marketed under the name Zydelig.</span></div>
